In individuals with T2DM and NAFLD, the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, like empagliflozin and dapagliflozin, lowers liver fat and raises ALT levels [153,154]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.